Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

被引:0
作者
Amir Ansaripour
Carin A. Uyl-de Groot
W. Ken Redekop
机构
[1] Erasmus University Rotterdam,Institute for Medical Technology Assessment, Institute of Health Policy and Management
来源
PharmacoEconomics | 2018年 / 36卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:91 / 103
页数:12
相关论文
共 355 条
[1]  
Ansaripour A(2016)Which is more important for doctors in a middle-income country, a national guideline or the medical literature? An adherence survey of trastuzumab use for breast cancer in Iran J Cancer Policy. 9 8-13
[2]  
Uyl-de Groot CA(2013)6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial Lancet Oncol 14 741-748
[3]  
Foroozanfar M(2013)2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Lancet. 382 1021-1028
[4]  
Rahimimoghadam S(2016)Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran Value Health. 19 A355-650
[5]  
Redekop WK(2012)Age at diagnosis and breast cancer survival in Iran Int J Breast Cancer. 2012 517976-5528
[6]  
Pivot X(2011)Prevalence of breast cancer in a defined population of Iran Iran Red Crescent Med J. 13 647-432
[7]  
Romieu G(2012)Standardized breast cancer mortality rate compared to the general female population of Iran Asian Pacific J Cancer Prev. 13 5525-36
[8]  
Debled M(2011)Updated Cost-effectiveness analysis of trastuzumab for early breast cancer PharmacoEconomics. 29 415-244
[9]  
Pierga J(2007)2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet. 369 29-1998
[10]  
Kerbrat P(2011)Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 236-391